IDEAYA Biosciences (IDYA) is back in focus after the FDA agreed to review its New Drug Application for darovasertib plus crizotinib in first line metastatic uveal melanoma under a Real-Time Oncology Review program.

Even with the FDA review decision and recent positive Phase 2/3 data, IDEAYA Biosciences’ share price has pulled back, with a 30 day share price return of a 13.21% decline and a year to date share price return of a 16.72% decline, while the 1 year total shareholder return stands at 34.69%. This pattern may reflect earlier optimism now meeting some profit taking and shifting risk views.

If this kind of oncology news has your attention, it can be a good moment to scan for other healthcare names riding similar themes through our 33 healthcare AI stocks

So with IDEAYA’s shares down this year despite FDA progress and positive trial data, is the market unfairly discounting the pipeline, or is it already factoring in much of the potential and any future growth at today’s price?

Preferred Price-to-Sales Multiple of 11.3x: Is it justified?

At the last close of $28.19, IDEAYA Biosciences screens as expensive on its preferred valuation yardstick, with a P/S of 11.3x that sits above several reference points in the data.

The P/S ratio compares the company’s market value to its revenue and is often used for unprofitable biotech names where earnings are still negative. In this case, IDEAYA is loss making, with revenue of $218.71 million and a reported net loss of $113.70 million. Investors are essentially paying for the revenue base and the potential attached to the pipeline rather than current profits.

In this context, the current 11.3x P/S is slightly higher than the US Biotechs industry average of 11x and also above a peer average of 7.1x, which suggests the market is assigning a richer revenue multiple than many comparables. The assessment that a fair P/S would be closer to 2.4x indicates a large gap between where the shares trade today and a level the data suggests the multiple could move toward if sentiment or assumptions reset.

Result: Price-to-Sales of 11.3x (OVERVALUED)

However, there are clear risks here, including clinical or regulatory setbacks across multiple programs and the possibility that current revenue and partnerships do not support the prevailing P/S premium.

Another view using the SWS DCF model

While the P/S ratio points to an expensive stock, the SWS DCF model points the other way, with an estimated future cash flow value of $276.11 per share versus the current $28.19 price. That gap frames IDEAYA as heavily undervalued on this lens. Which signal should matter more to you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IDEAYA Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on valuation and sentiment can be confusing, so instead of waiting for consensus to form, review the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If IDEAYA has sparked new questions for your portfolio, do not stop here. Use a focused stock screener to uncover other opportunities that fit your style.

• Target potential bargains by checking companies that combine quality fundamentals with attractive pricing through the 51 high quality undervalued stocks.
• Prioritise resilience by filtering for companies that show strong financial footing with the solid balance sheet and fundamentals stocks screener (44 results).
• Spot opportunities others may be overlooking by scanning the screener containing 25 high quality undiscovered gems before they are widely talked about.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.